Pharmos, Bausch & Lomb Pharmaceuticals Inc. regulatory update

The FDA approved PARS's Lotemax and Alrex, compounds that incorporate loteprednol etabonate, a site-specific steroid. Lotemax was approved to treat post-operative eye inflammation while Alrex treats...